Get the Stockscreener App
5.125
0.68%
0.015
After Hours:
4.99
-0.135
-2.63%
Lexeo Therapeutics Inc stock is traded at $5.125, with a volume of 455.21K.
It is up +0.68% in the last 24 hours and down -12.05% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
See More
Previous Close:
$5.11
Open:
$5.16
24h Volume:
455.21K
Relative Volume:
0.52
Market Cap:
$402.42M
Revenue:
$531.00K
Net Income/Loss:
$-99.96M
P/E Ratio:
-2.3382
EPS:
-2.1919
Net Cash Flow:
$-98.96M
1W Performance:
+14.84%
1M Performance:
-12.05%
6M Performance:
-46.57%
1Y Performance:
+82.45%
1-Day Range:
$5.07
$5.29
1-Week Range:
$4.48
$5.405
52-Week Range:
$2.5109
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
5.125 | 401.25M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Raymond James | Strong Buy |
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Lexeo Therapeutics (LXEO) Slips 2.29% as Stock Tests Key Support LevelsBPI Bear Correction - Newser
Lexeo Therapeutics Q1 2026 Earnings: EPS Beat on Lower Operating CostsProfit Announcement - Newser
LXEO Stock Chart | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics (LXEO) Sees Mild Gains as Stock Holds Above Key SupportMomentum Trade - Newser
Top Executive Makes Notable Move in Lexeo Therapeutics Stock - TipRanks
Lexeo (LXEO) COO sells 1,302 shares in tax-related stock sale - Stock Titan
Lexeo Therapeutics (LXEO) CEO sells 3,342 shares in tax-related RSU transaction - Stock Titan
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - Caledonian Record
LXEO (NASDAQ:LXEO) Rule 144 notice: 3,342 vested shares; prior sale 10,173 - Stock Titan
LXEO (NASDAQ: LXEO) lists restricted stock vesting; Form 144 shows past sale - Stock Titan
LXEO (NASDAQ: LXEO) insider sale notice — 1,595 vested shares - Stock Titan
Paradigm BioCapital holds 6.18M Lexeo shares (LXEO); 8.3% stake reported - Stock Titan
Balyasny groups disclose 7.18M shares in Lexeo Therapeutics (LXEO) - Stock Titan
Lexeo Therapeutics, Inc. (LXEO) Eps Diluted (TTM) - Zacks Investment Research
Lexeo Therapeutics Price Target Maintained With a $17.00/Share by Chardan Capital - Moomoo
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Lexeo Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Stifel Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Chardan Capital Reaffirms "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics, Inc. Q1 2026 10-Q Report: Financial Results, Forward-Looking Statements, and Key Disclosures - Minichart
Why Lexeo Therapeutics (LXEO) looks attractive at current levels (Parabolic) 2026-05-11Community Sell Signals - newser.com
Lexeo Therapeutics Reports Q1 2026 Results, Advances Cardiac Gene Therapy Pipeline, and Awaits FDA Feedback on Pivotal Trial - Minichart
Raymond James reiterates Strong Buy on Lexeo stock, $25 target By Investing.com - Investing.com Canada
Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lexeo Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Lexeo Highlights Q1 Progress Advancing Cardiac Gene Therapies - TipRanks
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights - The Manila Times
EDGAR Filing Documents for 0001193125-26-215674 - SEC.gov
Lexeo Therapeutics, Inc. 1Q 2026: Net income $(20.2M), EPS $(0.25) — 10-Q Summary - TradingView
Lexeo Therapeutics (NASDAQ: LXEO) posts lower Q1 loss with $227.6M cash - Stock Titan
Lexeo (Nasdaq: LXEO) trims Q1 loss and advances pivotal cardiac gene therapy plans - Stock Titan
Lexeo readies Friedreich ataxia pivotal trial, cash runway into 2028 - Stock Titan
Lexeo Therapeutics (LXEO) Price Target Increased by 19.77% to 21.29 - MSN
Lexeo Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
LXEO: Lexeo Therapeutics, Inc.Interactive Chart - Zacks Investment Research
The scenario planning at Lexeo Therapeutics (LXEO) | Q4 2025: EPS Beats ForecastsCommunity Buy Alerts - Newser
Why Lexeo Therapeutics (LXEO) ability to generate cash matters (Smart Money Active) 2026-05-06Turnaround Stocks - newser.com
Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Lexeo Therapeutics Adds Genomic Medicine Leader to Board - TipRanks
Lexeo Therapeutics (LXEO) director receives 50,000 stock options at $5.81 strike - Stock Titan
Lexeo Therapeutics (LXEO) director Laura Sepp-Lorenzino files Form 3 - Stock Titan
[ARS] Lexeo Therapeutics, Inc. SEC Filing - Stock Titan
Lexeo Therapeutics (NASDAQ: LXEO) details 2026 virtual meeting, board elections and pay - Stock Titan
Dr. Laura Sepp-Lorenzino joins Lexeo Therapeutics (LXEO) board and science committee - Stock Titan
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - The Manila Times
Lexeo Therapeutics to Present New Cardiac Gene Therapy Data at ASGCT Annual Meeting 2026 - Quiver Quantitative
Lexeo brings Friedreich ataxia, heart gene therapy data to Boston - Stock Titan
We Think Lexeo Therapeutics (NASDAQ:LXEO) Needs To Drive Business Growth Carefully - Moomoo
LXEO SEC FilingsLexeo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is Lexeo Therapeutics (LXEO) stock a good candidate for accumulation (Volatility Increases) 2026-04-20Social Buy Zones - UBND thành phố Hải Phòng
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
May 18 '26 |
Sale |
5.06 |
3,342 |
16,927 |
336,764 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):